Behavioral Neuroscience – News and Features

The National Institutes of Health has developed a research plan to advance understanding of Down syndrome and speed development of new treatments for the condition.

Researchers focuses on how Fragile X syndrome affects communication between cells in a region of the brain that is involved in learning and memory.

A whole-genome DNA analysis reveals a section of chromosome 16 that is deleted or duplicated in some people with autism spectrum disorders.

Difference in gene appears to pose more risk when inherited from mothers rather than fathers.

Researchers are uncovering how brain cells are affected in Fragile X syndrome, the most common cause of inherited mental retardation.

The deal aims to develop ADX63365, an orally available drug candidate for the potential treatment of schizophrenia and other undisclosed indications.

AstraZeneca has submitted two separate supplemental New Drug Applications to the US FDA for once-daily Seroquel XR™ Extended-Release Tablets.

In a study comparing brain activity of sober alcoholics and non-addicted people making financial decisions, the group of sober alcoholics showed more impulsive neural activity.

Evotec AG and Renovis, Inc. today announced that they have entered into a definitive agreement under which Evotec will acquire Renovis, a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of pain and inflammatory diseases, in a stock-for-stock transaction valued at approximately US$ 151.8 million.

Titan Pharmaceuticals’ Phase III efficacy and safety trials demonstrate that iloperidone is associated with greater improvements in the symptoms of schizophrenia versus placebo.